Publications

Development of an electronic health message system to support recovery after stroke: Inspiring Virtual Enabled Resources following Vascular Events (iVERVE)  Dominique Cadilhac et al. published in Patient Preference and Adherence.

Changes in bone microarchitecture following kidney transplantation - beyond bone mineral density.
Peter Ebeling et al. published in Clinical Transplantation.

Concentrating non-dilute urine before protein electrophoresis for the detection of monoclonal free light chains is unnecessary and wasteful. George Grigoriadis et al. published in Pathology.

Dobutamine treatment reduces inflammation in the preterm fetal sheep brain exposed to acute hypoxia. Flora Wong et al. published in Pediatric Research.

Perspectives of cancer treatment providers regarding voluntary assisted dying in Victoria. Peter Poon et al. published in the Internal Medicine Journal. 

Procalcitonin-guided antibiotic therapy algorithms for different types of acute respiratory infections based on previous trials. Yahya Shehabi et al. published in Expert review of anti-infective therapy. 

On the Developmental Timing of Stress: Delineating Sex-Specific Effects of Stress across Development on Adult Behavior. Rachel Hill et al. published in Brain Sciences. 

CD8+ cells and glomerular crescent formation: outside-in as well as inside-out. Maliha Alikhan, Richard Kitching published in the Journal of Clinical Investigation.

Animal models in neonatal resuscitation research: What can they teach us? Stuart Hooper et al. published in Seminars in Fetal and Neonatal Medicine.

THE MANY AND VARIED ROLES OF TETRASPANINS IN IMMUNE CELL RECRUITMENT AND MIGRATION. Louisa Yeung et al. published in Frontiers in Immunology.

Evaluating the Feasibility and Effectiveness of an Australian Safety Planning Smartphone Application: A Pilot Study Within a Tertiary Mental Health Service. Glenn Melvin et al. published in Suicide and Life Threatening Behavior.

Respiratory changes in term infants immediately after birth. Douglas Blank et al. published in Resuscitation.

DCEP regimen buys time for multiple myeloma patients

Dr George Grigoriadis

The combination of dexamethasone, cyclophosphamide, etoposide, and cisplatin (DCEP) is an effective bridge to autologous stem cell transplant (ASCT) or novel agents in patients with relapsed refractory multiple myeloma.

Original story in The Limbic.

DCEP as a bridge to ongoing therapies for advanced relapsed and/or refractory multiple myeloma

George Grigoriadis et al. published in Leukemia & Lymphoma.

Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma

George Grigoriadis et al. published in the British Journal of Haematology.

Read article here.

MHTP hosts Myeloma Australia event

Laura Jones, Dr George Grigoriadis, Dr Michael Low,
Associate Professor Jake Shortt, Elli Foley

Myeloma Australia welcomed over 60 people with myeloma, their families and friends to their "Monash Myeloma Update" last weekend.

Held for the first time in collaboration with Monash Health and Monash University, the half day event took place in the Translational Research Facility (TRF) at the Monash Health Translation Precinct (MHTP).

Associate Professor Jake Shortt presenting

Myeloma Australia support nurses Laura Jones and Elli Foley said the audience was excited to hear from leading speakers including Dr George Grigoriadis, Associate Professor Jake Shortt, and Dr Michael Low.

"Topics were well received and involved disease overview, treating myeloma and living well, and research updates specific to the MHTP," Laura said.

Immune thrombocytopenic purpura associated with fingolimod

George Grigoriadis et al. published in BMJ Case Reports.

Read article here.

Monash study identifies new high-risk group in multiple myeloma, allowing clinicians to intervene early to improve patient outcomes

Dr Pasquale Fedele

Early treatment response of newly diagnosed multiple myeloma patients should direct future therapy decisions, according to latest research at Monash University.

Myeloma, also known as multiple myeloma (MM), is a cancer of plasma cells (a type of white blood cell).  Each year in Australia around 1700 people are diagnosed with myeloma—the equivalent of four people every day.

Published last week  in the British Journal of Haematology, the collaborative Monash University and Monash Health study has revealed that the way MM patients respond to treatment after just two cycles of bortezomib, a new class of anti-cancer drug, determines outcomes and should guide future treatment decisions.

Lead researcher Monash Health haematologist Dr Pasquale Fedele said the introduction of two classes of medications, the immunomodulatory drugs and the proteasome inhibitors - collectively referred to as the ‘novel agents’, has dramatically improved the outcomes of patients with multiple myeloma. However, clinicians are still learning how best to utilise these medications.

“Although triplet induction regimens administering both novel agents concurrently are widely considered ‘gold standard’, the costs of such protocols are prohibitive for many healthcare systems,” Dr Fedele said.

“Furthermore, combinational therapy may increase the risk of toxicity, and a greater number of patients appear unable to tolerate these more intensive regimens.”

“It is important therefore that we identify which patients actually need this more intensive treatment versus those who are likely to do well with standard regimens”.  

Dr George Grigoriadis

Study co-author Dr George Grigoriadis, a Monash Health haematologist and Monash University researcher said currently it isn’t known whether stratification, based on patients achieving specific milestones early in their treatment, will identify which patients ‘in real time’ are likely to have poor long-term outcomes and therefore may benefit from early escalation of therapy.

The research team conducted a retrospective review of all newly diagnosed MM patients at Monash Health who were treated with bortezomib, a proteasome inhibitor, between 2012 and 2016.

“Our study results demonstrate that patients who fail to respond after two cycles of bortezomib have poorer survival rates compared to those who do, suggesting that this group of patients may benefit from early treatment escalation,” Dr Grigoriadis said.

“Importantly however, current prognostication based on cytogenetics and clinical factors at diagnosis does not identify this poor risk group.”

The study authors are now advocating for early stratification to be incorporated into the design of future clinical trials for MM, to determine if directed treatment escalation results in improved outcomes for this vulnerable group of patients.

Failure to achieve early disease response is associated with inferior survival in patients with newly diagnosed multiple myeloma

Pasquale Fedele, George Grigoriadis et al. published in the British Journal of Haematology.

Read article here.

Improving the Transition to Palliative Care for Patients With Acute Leukemia: A Coordinated Care Approach

George Grigoriadis et al. published in Cancer Nursing.

Read article here.

Iron deficiency and new insights into therapy

George Grigoriadis, MS Low published in the Medical Journal of Australia.

Read article here.

Periorbital papules as a presenting sign in multiple myeloma with AL amyloidosis.

George Grigoriadis et al. published in BMJ Case Reports.

Read article here.

Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.

George Grigoriadis et al. published in Internal Medicine Journal.

Read article here.

Acute monocytic leukemia masked by hemolytic anemia and sclerotic lesions.

George Grigoriadis et al. published in Annals of Hematology.

Read article here.

Profiling clinical platelet and plasma use to inform blood supply and contingency planning: PUPPY, the prospective utilization of platelets and plasma study

George Grigoriadis et al. published in Transfusion.

Read article here.

Acute monocytic leukemia masked by hemolytic anemia and sclerotic lesions

George Grigoriadis et al. published in Annals of Hematology.

Read article here.

Rivaroxaban in treatment refractory heparin-induced thrombocytopenia

Joshua Casan, George Grigoriadis et al. published in BMJ Case Reports.

Read article here.

State of the Art Lecture - Haematology Unit - 22/06/2016 - Myeloma: A Cook’s tour and the role of minimal residual disease assessment

Unit:                Haematology Unit

Topic:              Myeloma: A Cook’s tour and the role of minimal residual disease assessment

Presenter:      Dr George Grigoriadis

Date:               Wednesday 22 June 2016

Time:               12.30pm to 1.30pm

Venue:            Main Lecture Theatre, Monash Medical Centre, Clayton.

Anabolic androgenic steroids, an easily forgotten cause of polycythaemia and cerebral infarction

George Grigoriadis et al. published in Internal Medicine Journal.

Read article here.

The SMAC mimetic, LCL-161, reduces survival in aggressive MYC-driven lymphoma while promoting susceptibility to endotoxic shock

 Jake Shortt et al. published in Oncogenesis.

Read article here.

NFκB1 is essential to prevent the development of multiorgan autoimmunity by limiting IL-6 production in follicular B cells

George Grigoriadis et al. published in the Journal of experimental medicine.

Read article here.